493. From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction (Jim Tananbaum)

Jim Tananbaum of Foresite Capital joins Nick to discuss From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction. In this episode we cover:

• Data Science and Investment Approach
• Investment Practices and Market Conditions
• China's Role in Biotech and Regulatory Considerations
• Impact of AI on Biotech and Healthcare
• Healthcare Adoption of AI and Preventive Measures
• Payers and Insurance Companies' Role
• Lessons from Successful Investments
• Generating Liquidity in a Sluggish Market
• Future of GLP-1 Agonists

Guest Links:

• Jim's LinkedIn
• Jim's X
• Foresite's LinkedIn
• Foresite's Website

The host of The Full Ratchet is Nick Moran of New Stack Ventures, a venture capital firm committed to investing in founders outside of the Bay Area.

We're proud to partner with Ramp, the modern finance automation platform. Book a demo and get $150—no strings attached.

Want to keep up to date with The Full Ratchet? Follow us on social. You can learn more about New Stack Ventures by visiting our LinkedIn and Twitter.